Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NRXP: Effective Tues. April 2,2024 a one for 10 reverse split:
https://hedgefollow.com/upcoming-stock-splits.php
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
Four potential near-term milestones, including data from two clinical trials, an NDA filing and a share dividend
RADNOR, Pa., March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announces its anticipated financial results for the quarter and year ended December 31, 2023 and provides the following summary of its expected annual report to be filed later today.
Improvement in negative Earnings per Share to ($0.40) in FY 2023 vs ($0.60) in prior 12 month period. Management projects positive cash flow by year-end 2024 via partnerships and HOPE Therapeutics activities.
Raised $9.2 in new capital during FY 2023 with $7.8 million of additions to working capital during Q1 2024. Reduced corporate indebtedness by more than 50% from $11.0 million to approximately $5.4 through Q1 2024.
Signed a development partnership with Alvogen, Inc., and Lotus Pharmaceuticals, Inc. (1795.TW) under which the partners take over phase 3 and commercial costs for NRX-101 in bipolar depression and fund $330 million in commercial milestones together with a double digit royalty on sales, contingent on successful clinical trial data and FDA meeting.
Completed enrollment and last patient visit of the Phase 2b/3 trial of NRX-101 in Suicidal Bipolar Depression with >94% rater concordance through conclusion of the trial, a measure that substantially exceeds current industry standards. Final Data Lock expected this week with Top line data expected in April 2024.
Acceptance of two new Investigational New Drug applications (INDs) by the FDA in Chronic Pain and Complicated Urinary Tract Infection/Pyelonephritis.
Final statistical analysis plan achieved this week in 200-person DOD-funded trial in treatment of chronic pain with D-cycloserine (DCS), the key component of NRX-101. The study center has indicated that data-lock will occur next week. Top-line data expected in April 2024. Positive data would support a final registration trial in this multi-billion dollar indication.
Incorporated HOPE Therapeutics, Inc. as a specialty pharma company. HOPE is supporting distribution of intravenous ketamine, currently listed by FDA on nationwide drug shortage list to qualified ketamine clinics through nationwide 503a and 503b FDA-inspected pharmacy partners. First manufactured lot released for shipment this week by partner Nephron Pharmaceuticals.
Obtained patient-level data from three efficacy studies of ketamine funded by US National Institutes of Health (two trials) and Government of France (one trial). Demonstration statistically significant reduction in severe depression and acute suicidality. US Patient Centered Outcomes Research Initiative (PCORI) trial published in 2023 documents non-inferiority of ketamine vs Electroconvulsive Therapy in treatment of Severe Depression with fewer negative side effects compared to ECT.
Completed first commercially-manufactured lot of ketamine (NRX100/HTX-100) in proprietary diversion-resistant presentation and initiated manufacture of two additional commercial batches. Anticipates filing of New Drug Application for treatment of Acute Suicidality by June 2024 upon completion of required 9 month stability and CMC with anticipated 2024 PDUFA date.
HOPE has received term sheets for more than $60 million in funding from new investors upon public listing and is expected to be spun out as a separate company to be owned by NRx, current NRx shareholders, and new investors upon completion of final audit and financial statements
IND for NRX-101 in the treatment of Complicated Urinary Tract Infection (cUTI) is based on in vitro data just accepted for peer-reviewed publication in Antibiotics, an MDPI journal. On the basis of these findings, FDA granted Qualified Infectious Disease Product (QIDP),Fast Track and Priority Review designations NRx is seeking a clinical phase partner for this multi-hundred million dollar indication.
Elected nationally recognized attorney in highly regulated industries, and healthcare specialist, Janet Rehnquist, Esq., to the Company's Board of Directors
Management has taken action to restore Nasdaq listing compliance and combat illegal naked shorting of NRx securities
Management to host a conference call April 1, 2024 at 8:30am (conference call to be conducted after Easter market holiday.
"Over the past year the Company has navigated the most challenging business environment in the history of the biotechnology industry. Despite unprecedented headwinds, we negotiated a critical commercial partnership for our lead compound in bipolar depression, while retaining rights to the far larger indications of chronic pain and PTSD," said Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. "We augmented our intellectual property portfolio to include the use of our lead compound in chronic pain and anticipate results of a 200-person efficacy trial that could open a multibillion dollar opportunity in this therapeutic area. We have acquired sufficient data on safety and efficacy of ketamine to support a New Drug Application for ketamine in acute suicidality. We established the foundation of a specialty pharmaceutical business around ketamine that we expect to yield positive cash flow by the end of 2024. Finally, we received unanticipated data supporting the use of our lead compound to treat complicated Urinary Tract Infection and Pyelonephritis, a condition that affects 3 million Americans and results in more than 15,000 deaths annually. We believe that NRx is poised for substantial growth in 2024 look forward sharing further results in our upcoming filing and conference call."
A final press release on the 10-k filing will be issued Monday April 1, following the market holiday.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, including statements about the planned dividend of shares of HOPE Therapeutics, the potential effects of the Company's reverse stock split, potential future stock splits, data from clinical trials that have not yet been released, and planned filings with the FDA. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL73218&sd=2024-03-28 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-reports-preliminary-fourth-quarter-and-full-year-2023-financial-results-and-provides-year-end-highlights-302102518.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP News: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) today announces its anticipated financial results for the quarter and year ended December 31, 2023.
Read More - https://ir.nrxpharma.com/2024-03-28-NRx-Pharmaceuticals-NASDAQ-NRXP-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Year-End-Highlights
#NRxPharma #PharmaNews #NRX100 #NRX101 $NRXP
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) today announces its anticipated financial results for the quarter and year ended December 31, 2023.
— NRx Pharmaceuticals (@NRxPharma) March 28, 2024
Read More - https://t.co/C7UTC5uwHY#NRxPharma #PharmaNews #NRX100 #NRX101 $NRXP
$NRXP #Due to scheduling conflicts and Good Friday stock market holiday, NRx Pharmaceuticals will now host its conference call to discuss the financial results and corporate update on Monday, April 1, 2024, at 8:30 a.m. ET. https://ir.nrxpharma.com/index.php?s=43&item=223
Due to scheduling conflicts and the Good Friday stock market holiday, NRx Pharmaceuticals will now host its conference call to discuss the financial results as well as provide a corporate update on Monday, April 1, 2024, at 8:30 a.m. ET.
— NRx Pharmaceuticals (@NRxPharma) March 27, 2024
Read More - https://t.co/c3MQToYP5X
$NRXP .55 +6.59% UPDATE OUT: NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-report-200300524.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via Yahoo Finance #news #update
$NRXP - May is Mental Health Month 2024. Download the toolkit here: http://buff.ly/3aQwaXb
#mentalillness #mentalhealth #mentalhealthawareness #mentalhealthmatters #depression #ketamine #stress #PTSD #bipolar #NRX100 #NRX101 $NRXP $RENB NRx Pharmaceuticals, Inc.
$NRXP @NRxPharma Planned Public Stock Dividend, Royalty Rights Pledged to Shareholders for Valuable Ketamine Franchise: NASDAQ: NRXP https://www.einpresswire.com/article/696916460/planned-public-stock-dividend-royalty-rights-pledged-to-shareholders-for-valuable-ketamine-franchise-nasdaq-nrxp via @ein_news For more information on $NRXP visit: https://www.nrxpharma.com/ and https://axecapitalusa.com/nrxp/
$NRXP News: NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
PR Newswire
Mon, Mar 25, 2024, 8:30 AM EDT5 min read
In This Article:
NRXP
+10.87%
NRXPW
0.00%
RADNOR, Pa., March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.
The Ketamine 2024 Conference assembles many of the top scientists and clinicians in the field from around the world and is a forum for top researchers and experienced and interested clinicians to learn from each other about the therapeutic use of Ketamine and related compounds for affective disorders.
Dr. Javitt will present a keynote talk titled, "Ketamine: the Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced." He will present an overview of the rapid and dramatic efficacy of Ketamine in the treatment of acute suicidality as well as recent science documenting the potential for neurotoxicity with long-term CNS side effects if ketamine is used without appropriate safety controls as a long-term drug.
"HOPE Therapeutics builds upon four decades of scientific discovery related to the role of the brain's NMDA receptor and the effects of ketamine and other NMDA-antagonist drugs in rapidly attenuating symptoms of depression and suicidality. It is an honor for our company to be invited to share a platform with those who have established this field of science and who may forever change the outlook and future path of patients who suffer from suicidal depression and PTSD," said Dr. Javitt.
Ketamine 2024 Conference Presentation
When: Monday, March 25th, 2024
Time: 1:40-2:00 PM GMT
Title: Ketamine: The Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-chairman-dr-jonathan-javitt-to-present-at-the-ketamine-2024-conference-in-oxford-uk-302097763.html
SOURCE NRx Pharmaceuticals, Inc.
Good morning $NRXP more updates!
$NRXP News: NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
PR Newswire
Thu, Mar 21, 2024, 4:02 PM EDT2 min read
In This Article:
NRXP
+12.29%
RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30 p.m. ET the same day.
A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-877-704-4453, Int'l Investors Dial 1-201-389-0920.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2023-financial-results-and-provide-a-corporate-update-on-march-28-2024-302096432.html
SOURCE NRx Pharmaceuticals, Inc.
$NRXP .59 +16.81% Breaking out! New HOD .60
$NRXP Friday's Open @.56 10.87% #bullish #shortsqueeze
$NRXP .5001 +3.11% Bullish chart forming on NEWS!
$NRXP NEWS OUT! NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) today announced the results of the vote held during today's Special Meeting of Shareholders.
Read More - https://ir.nrxpharma.com/2024-03-21-NRx-Pharmaceuticals-Announces-Results-of-the-Vote-Held-During-the-Special-Meeting-of-Shareholders
#NRxPharmaceuticals #NRxPharma #PharmaNews #NRX100 #NRX101 $NRXP
$NRXP NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
"Initiative is intended to protect shareholder value through continued compliance with Nasdaq listing rules and elimination of naked short sales positions in the Company's securities" https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-initiates-114900937.html
$NRXP @elonmusk Elon Musk said that his prescribed use of ketamine alleviates periods of low mood and is in the best interest of investors in Tesla Inc.
[ @gravyman) is superior. https://bloomberg.com/news/articles/2024-03-18/musk-says-ketamine-prescription-is-in-investors-best-interests #TSLA #FDA #News
$NRXP .4899 HOD .54 NRx Pharma Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
Love the NRXP dividend news. This is the best way to reward investors who are supporting the company and also a pressure to drive short sellers out. When a company issues a dividend, shorts are liable to pay the value of that dividend rather than receiving it as they are not the true owners of the stock.
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-123000925.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
Any thoughts on the vote for RS? I know about the theory behind it, but it seams like if they had confidence over the future of their three candidate drugs then the SP would easily and soon enough pop over the edge of a buck.
$CBDW @CBDWInc 1606 Corp. Building on success of its first marketing campaign
$NRXP .54 +4.85% nice move pre-market may open higher!
Elon Musk Says His Ketamine Prescription Matters to Investors
https://www.bloomberg.com/news/articles/2024-03-18/musk-says-ketamine-prescription-is-in-investors-best-interests
Elon Musk Says His Ketamine Prescription Matters to Investors Interesting article...
Elon Musk said that his prescribed use of ketamine alleviates periods of low mood and is in the best interest of investors in Tesla Inc. and the other companies he runs.
For Wall Street, “what matters is execution,” Musk said in an interview with former CNN anchor Don Lemon streamed Monday on YouTube. “From an investor standpoint, if there is something I’m taking, I should keep taking it,” he said referring to Tesla’s success.
Musk said he takes the drug as prescribed periodically to treat what he described as “chemical tides” that lead to depression-like symptoms. Doctors can prescribe ketamine to treat pain and depression and at higher doses, the drug acts as a sedative. It can also cause hallucinations, and overdosing can lead to unconsciousness and dangerously slowed breathing, according to the US Drug Enforcement Administration.
An article in the Wall Street Journal in January said that executives in the Tesla and SpaceX chief executive officer’s companies had grown concerned about his recreational drug use. Musk responded that he hadn’t failed drug tests and, in a post on his X social network, that “whatever I’m doing, I should obviously keep doing it!”
$NRXP NEWS! NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders @NRxPharma #news #dividends #announced https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-123000925.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$NRXP More DD: #nasdaq "NRX-100 - A Beacon of Light in the Darkness of Acute Suicidality and Depression" https://axecapitalusa.com/nrxp/
$NRXP Short Interest https://www.nasdaq.com/market-activity/stocks/nrxp/short-interest #shortsqueeze
$NRXP 0.475 +2.59% HOD .4859 Looks to be moving back into the .50 cent range!
$NRXP - Company has retained former SEC enforcement leadership to notify leading brokerages of the need to close all naked short positions in the Company's securities and to prevent future accumulation of naked short positions in the Company's new security
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-initiates-114900937.html
$NRXP .4699 +6.94% Resilient After yesterdays Dip - NRX Pharmaceuticals Inc NASDAQ
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-initiates-114900937.html
Excellent News today... Let's see how this initiative goes!
$NRXP
$NRXP Agreed! With the Nasdaq they run on news. Shorts need to close positions but yeah longs may benefit if it does well. It's different when larger hedge funds can invest at higher prices as well. FDA news and it explodes. RS may be frowned upon in OTC but this is Nasdaq.
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
PR Newswire
Tue, Mar 12, 2024, 7:49 AM EDT
Initiative is intended to protect shareholder value through continued compliance with Nasdaq listing rules and elimination of naked short sales positions in the Company's securities
The Company is contemplating a reverse split, if needed to maintain NASDAQ listing compliance, to be accompanied by change in corporate name and CUSIP number
Company has retained former SEC enforcement leadership to notify leading brokerages of the need to close all naked short positions in the Company's securities and to prevent future accumulation of naked short positions in the Company's new security
RADNOR, Pa., March 12, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") today initiated actions to combat short sellers in the Company's stock.
The Company announced a proposal to simultaneously change the CUSIP under which the Company's shares are traded, together with changing the name of the Company to NRx Therapeutics, Inc. The Company plans to accompany these actions with a required exchange of the underlying stock certificates. This certificate change is expected to be seamless for those investors holding NRXP shares in electronic form and similarly for investors who may have established short positions in NRXP by borrowing the underlying shares from a registered shareholder. Any party holding a short position in the Company's shares who has not complied with the legal requirement to borrow the underlying shares of stock (i.e. "a naked short") may be unable to exchange that position for a position in the new security.
The Company is working with attorneys who formerly served in leadership positions at the SEC Division of Enforcement to correspond with corporate counsel and compliance heads at leading brokerages to emphasize the current legal prohibitions against naked short sales. As identified in previous announcements, the Company was advised by ShareIntel in September 2023 that substantial naked short positions in the Company's securities had been identified at major brokerage firms.
"We believe it is in the best interests of our shareholders to have fully-compliant trading in the markets," said Janet Rehnquist, Esq., who chairs the Company's Compliance Committee. "As we focus on the development of potentially life-saving drugs to combat suicidal depression, PTSD, and Chronic Pain, it is critical that we take all steps possible to maximize the value of those who have invested in our Company and provided the resources to address these critical unmet medical needs."
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
CisionCision
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-initiates-strategy-to-combat-short-sales-302086668.html
SOURCE NRx Pharmaceuticals, Inc.
The SEC filing is on the website describing the special meeting and reverse split.
DEF 14A Official notification to shareholders of matters to be brought to a vote ("Proxy") filed on March 11, 2024
https://ir.nrxpharma.com/sec-filings
NASDAQ listing requires 10 consecutive days above $1.00 to remain listed so suspect something in the 1:5 to 1:10 range although 1:2 would work if it holds. Probably be safe and go to a higher ratio. TWT.
$NRXP .6825 +11.27% in power hour! Great day for NRX Pharma as NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) https://ir.nrxpharma.com/2024-03-11-NRx-Pharmaceuticals-NASDAQ-NRXP-Completes-Memorandum-of-Understanding-and-Collaborations-with-Distribution-Partners-for-HTX-100-IV-Ketamine
$NRXP @NRxPharma NRx Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression #MarketScreener https://www.marketscreener.com/quote/stock/NRX-PHARMACEUTICALS-INC-38908842/news/NRX-Pharmaceuticals-Announces-Last-Patient-Last-Visit-in-Its-Phase-2B-3-Trial-of-NRX-101-in-Suicida-46092753/?utm_source=twitter&utm_medium=social&utm_campaign=share
$NRXP looking good on today's News, UP almost 11% on nearly 20% of its 10-day average volume within the first hour.
Company to receive first allocation of ketamine for sale by month end
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-completes-123000827.html
$NRXP .685 +11.67% Based on 2 Wall Street analysts offering 12 month price targets for NRX Pharmaceuticals in the last 3 months. The average price target is $3.75 with a high forecast of $5.50 and a low forecast of $2.00. The average price target represents a 459.70% change! huge #NEWS #OUT
$NRXP News: NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
PR Newswire
Mon, Mar 11, 2024, 8:30 AM EDT
- Company to receive first allocation of ketamine for sale by month end
- Partners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmacies
- NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply
- Important step toward goal of providing full suite of supply options, to ultimately include an FDA approved, and widely reimbursed, solution for patients and clinics, subject to board approval
RADNOR, Pa., March 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") and its wholly owned subsidiary HOPE Therapeutics, clinical-stage biopharmaceutical companies, today announced completion of a Memorandum of Understanding with Conversio Health, a national 503a pharmacy, and a strong, ongoing partnership with Nephron Pharmaceuticals, a manufacturer of Ketamine and 503b pharmacy to provide IV Ketamine to patients and clinics across the country, subject to board approval. These are important steps to providing a full suite of ketamine options for customers across the country, and preparation for potential approval of HTX-100 by regulatory authorities worldwide.
The Company has further entered into a business relationship with an organization that currently serves the business needs of more than 100 ketamine clinics nationwide. The Company has been given a target delivery date prior to the end of this month (March 2024) for initial stock of ketamine for sale to licensed end users. Sales are planned to commence once technical and logistical elements are finalized. Details for ordering will be available on our website as soon as they are available. www.hopetherapeutics.com
In contrast to NRx Pharmaceuticals, which is structured as a Biotechnology research and development company, HOPE Therapeutics is structured as a Specialty Pharmaceutical company that aims to supply a variety of therapeutic products to clinics that are treating suicidal depression and PTSD, including both traditional and digital therapeutics.
"We are pleased to be working with two outstanding organizations in Conversio Health and Nephron Pharmaceuticals to provide this important medication to a market in need of a consistent supply of high-quality, FDA- and DEA- compliant IV ketamine," said Matthew Duffy Chief Business Officer of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics. "Importantly, these efforts will provide a strong foundation for expanding our product offering with our planed filing a New Drug Application with the FDA in the coming months, and the potential launch of HTX-100 in early 2025." The NDA filing currently awaits completion of an additional three months of product stability.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through HOPE Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.)
HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.)
CisionCision
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-completes-memorandum-of-understanding-and-collaborations-with-distribution-partners-for-htx-100-iv-ketamine-302085271.html
SOURCE NRx Pharmaceuticals, Inc.
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-completes-123000827.html
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company") and its wholly owned subsidiary HOPE Therapeutics, clinical-stage biopharmaceut...
$NRXP With a Novel Breakthrough Drug, This Little-Known Biotech Company is on the verge of significant FDA results.
Of the thousands of drugs approved by FDA, only 544 have been designated as “Breakthrough Therapy.” NRX-101 is the first Breakthrough Therapy for Suicidal Depression https://axecapitalusa.com/nrxp/
$NRXP .62 HOD .65 Huge Volume! @NRxPharma
NRx Pharmaceuticals Hits Milestone in Suicidal Bipolar Depression Treatment; Potential $329 Million Deal with Partners: NRXP https://www.einpresswire.com/article/693114260/trial-endpoint-for-1st-suicidal-bipolar-ptsd-pain-drug-partners-can-provide-329-million-royalties-nasdaq-nrxp via @ein_news
$NRXP .6885 +3.85% Trial Endpoint Reached for First Suicidal Bipolar Depression, Chronic Pain and PTSD Drug; Agreement with Partners Can Provide up to $329 Million and Royalties: NRx Pharmaceuticals (Nasdaq: NRXP) https://www.benzinga.com/pressreleases/24/03/ab37472614/trial-endpoint-reached-for-first-suicidal-bipolar-depression-chronic-pain-and-ptsd-drug-agreement via @Benzinga
$NRXP .6599 +26.90% Great interview out! The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals.
Watch Interview - https://nrxpharma.com/the-big-biz-show-interviews-jonathan-c-javitt-m-d-m-p-h-chief-scientist-director-and-founder-nrx-pharmaceuticals-3/
#mentalhealth #depression #suicide #bipolar #PTSD #NRX100 #ketamine #NRXPharma #PharmaNews $NRXP
$NRXP up pre-market .5414 +4.12% as NRx Pharma marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression.
2x Phase 3 readouts expected in early Q2 while valuation is still super low at $44 million
NRXP MOVING UP NOW
Followers
|
55
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1154
|
Created
|
12/15/20
|
Type
|
Free
|
Moderators ProfitScout jedijazz |
Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect...
New data demonstrates no impact of NRX-101 on gut or vaginal flora – considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infections NRX-101 previously...
Formulation based on prior patents by NRx founder Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration Company expects...
Data transferred for independent statistical analysis Top-line data expected in April 2024 RADNOR, Pa., April 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx...
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend -- 50% reduction in corporate overhead and 25% reduction in overall net...
Four potential near-term milestones, including data from two clinical trials, an NDA filing and a share dividend RADNOR, Pa., March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist...
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year...
61.4% (56,781,354) of eligible shares voted 94.4% of votes were cast in favor of the resolution RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx...
NRx Pharmaceuticals Board of Directors has authorized its Chairman, CEO, and management to take all necessary steps to affect the Dividend and Royalty Rights to NRXP Shareholders and applicable...
Initiative is intended to protect shareholder value through continued compliance with Nasdaq listing rules and elimination of naked short sales positions in the Company's securities The Company is...
Company to receive first allocation of ketamine for sale by month end Partners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmacies NRx Pharmaceuticals and HOPE...
Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression The study database is being cleaned and locked; statistical analysis and top-line...
NRx Pharmaceuticals received approximately $1.0 million in cash from an existing investor Shares were sold at $0.38, a 26.7% premium the recent share offering, along with one common 5-year warrant...
In the news release, NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock, issued 27-Feb-2024 by NRx Pharmaceuticals, Inc. over PR Newswire, we...
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its...
Presentation available on NRx Pharmaceuticals website at https://www.nrxpharma.com/hope-therapeutics/ KEY UPDATES ARE AS FOLLOWS: NRx management is proposing to award 50% of founding shares in...
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |